Biocon Pharma Inc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Biocon Pharma Inc Pharmaceutical Import Records from India — 7 Products, $110.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Biocon Pharma Inc — Pharmaceutical Importer Profile (2026) | 7 Products, $110.0M Trade | TransData Nexus

Biocon Pharma Inc

Pharmaceutical Importer · United States · Vitamins & Supplements Focus · $110.0M Total Trade · DGFT Verified

Biocon Pharma Inc is a pharmaceutical importer based in United States with a total trade value of $110.0M across 7 products in 4 therapeutic categories. Based on 2,231 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Biocon Pharma Inc sources from 4 verified Indian suppliers, with Biocon Pharma Limited accounting for 76.2% of imports.

Biocon Pharma Inc — Import Portfolio & Supplier Network

Biocon Pharma Inc import network — 7 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Biocon Pharma Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Biocon Pharma Limited	$40.9M	1,070	76.2%
Graviti Pharmaceuticals Private Limited	$12.1M	357	22.5%
Acme Generics Private Limited

What Formulations Does Biocon Pharma Inc Import?

Formulation	Value	Ships
Esomeprazole magnesium delayed release	$1.8M	53
Atorvastatin calcium tablets USP 40MG	$930.4K	31
Atorvastatin calcium tablets USP 40MG	$924.6K	19
Atorvastatin calcium tablets USP 10MG	$750.0K	15
Atorvastatin calcium tablets USP 80	$714.1K	26
Rosuvastatin calcium tablets 40MG (30s	$704.2K	22
Rosuvastatin calcium tablets 10MG (90s	$650.0K	13
Atorvastatin calcium tablets USP 80MG	$568.8K	14
Rosuvastatin calcium tablets 20MG (90s	$500.0K	10
Rosuvastatin calcium tablets 20MG (500s	$450.0K	9
Atorvastatin calcium tablets USP 80MG	$439.9K	15
Atorvastatin calcium tablets USP 20MG	$433.0K	12
Rosuvastatin calcium tablets 40MG (30s	$426.6K	9
Atorvastatin calcium tablets USP 20	$402.1K	16
Atorvastatin calcium tablets USP 40MG	$400.0K	8

Biocon Pharma Inc imports 746 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 7 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Calcium	Vitamins & Supplements	$48.6M	973	5.4%	4
2	Rosuvastatin	Cardiovascular	$29.6M	593	6.4%	2
3	Atorvastatin	Cardiovascular	$16.0M	339	1.5%	9
4	Esomeprazole	Gastrointestinal	$7.6M	158	1.7%	10
5	Magnesium	Vitamins & Supplements	$7.6M	158	2.1%	8
6	Tacrolimus	Immunosuppressants	$350.0K	7	0.2%	18
7	Everolimus	Immunosuppressants	$150.0K	3	0.4%	10

Biocon Pharma Inc imports 7 pharmaceutical products across 4 categories into United States totaling $110.0M.

Biocon Pharma Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Biocon Pharma Inc. is a U.S.-based pharmaceutical importer specializing in the acquisition of finished pharmaceutical formulations from India. Headquartered in Iselin, New Jersey, the company operates as a subsidiary of Biocon Limited, an Indian multinational biopharmaceutical company. Biocon Limited, founded in 1978 by Kiran Mazumdar-Shaw, is renowned for its extensive portfolio in generics, biosimilars, and research services.

In the United States, Biocon Pharma Inc. plays a pivotal role in the pharmaceutical distribution network by sourcing a diverse range of finished dosage forms from Indian manufacturers. This strategic sourcing enables the company to offer cost-effective and high-quality pharmaceutical products to the U.S. market, thereby enhancing access to essential medications. The company's operations are integral to the broader supply chain, connecting Indian pharmaceutical manufacturers with U.S. healthcare providers and consumers.

2Distribution Network

Biocon Pharma Inc. maintains a robust distribution network within the United States, with its primary operations based in Iselin, New Jersey. While specific details regarding additional warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic positioning in New Jersey facilitates efficient access to major U.S. markets. This location offers proximity to key transportation hubs, including ports and airports, which is advantageous for the timely distribution of pharmaceutical products.

The company's distribution network is designed to ensure the seamless importation and delivery of pharmaceutical formulations sourced from India. By leveraging its New Jersey base, Biocon Pharma Inc. can effectively manage logistics, maintain inventory levels, and meet the demands of the U.S. healthcare sector. This operational efficiency underscores the company's commitment to providing reliable access to essential medications across the United States.

3Industry Role

Biocon Pharma Inc. functions as a pharmaceutical importer and distributor within the United States, specializing in sourcing finished pharmaceutical formulations from Indian manufacturers. By importing a diverse array of pharmaceutical products, the company serves as a critical link between Indian pharmaceutical producers and the U.S. market. This role is particularly significant given India's status as a major global supplier of generic drugs, with a substantial portion of U.S. generic drug consumption originating from Indian firms.

Through its importation activities, Biocon Pharma Inc. contributes to the diversification and resilience of the U.S. pharmaceutical supply chain. By offering a range of cost-effective and high-quality medications, the company supports the U.S. healthcare system in meeting the needs of patients and healthcare providers. This strategic positioning enables Biocon Pharma Inc. to play a vital role in enhancing access to essential pharmaceuticals across the United States.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Biocon Pharma Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Biocon Pharma Inc.'s sourcing strategy exhibits a high degree of concentration, with a significant majority of its imports originating from a select group of Indian suppliers. The company's total import value from India stands at $110.0 million USD, encompassing 2,231 shipments and 746 unique formulations across seven products in four therapeutic categories. Notably, the top five products account for 99.5% of the total import value, indicating a strong reliance on a narrow product range.

The primary supplier, Biocon Pharma Limited, contributes $40.9 million USD (76.2% of total imports) through 1,070 shipments. Secondary suppliers include Graviti Pharmaceuticals Private Limited ($12.1 million USD, 22.5% share), Acme Generics Private Limited ($470K, 0.9% share), and Biocon Biologics Limited ($193K, 0.4% share). This supplier distribution suggests a strategic choice to maintain close partnerships with a few key manufacturers, potentially facilitating streamlined operations and quality control.

However, the high concentration in both product offerings and supplier base may pose risks related to supply chain disruptions, pricing volatility, and dependency on specific manufacturers. Diversifying the product portfolio and expanding the supplier base could mitigate these risks and enhance the company's resilience in the face of market fluctuations or operational challenges.

2Supply Chain Resilience

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA's mission includes ensuring that imported drugs meet the same standards for quality, safety, and effectiveness as those produced domestically.

Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act (FD&C Act), which outlines the requirements for drug approval, manufacturing practices, and labeling. The FDA enforces these regulations to protect public health by preventing the entry of adulterated, misbranded, or unapproved drugs into the U.S. market.

For Indian pharmaceutical exporters, understanding the FDA's regulatory framework is crucial for ensuring compliance and facilitating the successful importation of their products into the United States.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are governed by the FDA. Importers must ensure that their products comply with FDA regulations, including those related to Good Manufacturing Practices (GMP). The FDA recognizes GMP certifications from reputable international bodies, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications serve as evidence that manufacturing facilities adhere to internationally accepted quality standards.

Biocon Pharma Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Biocon Pharma Inc.'s product strategy focuses on importing pharmaceutical formulations across four therapeutic categories: Vitamins & Supplements, Cardiovascular, Gastrointestinal, and others. The top five products imported—Calcium, Rosuvastatin, Atorvastatin, Esomeprazole, and Magnesium—account for 99.5% of the total import value, indicating a concentrated product portfolio.

The emphasis on these specific therapeutic areas aligns with market demand for essential medications in the U.S. market. Calcium and magnesium supplements address widespread nutritional needs, while statins like Rosuvastatin and Atorvastatin are critical for managing cardiovascular

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Biocon Pharma Inc

What products does Biocon Pharma Inc import from India?

Biocon Pharma Inc imports 7 pharmaceutical products across 4 categories. Top imports: Calcium ($48.6M), Rosuvastatin ($29.6M), Atorvastatin ($16.0M), Esomeprazole ($7.6M), Magnesium ($7.6M).

Who supplies pharmaceuticals to Biocon Pharma Inc from India?

Biocon Pharma Inc sources from 4 verified Indian suppliers. The primary supplier is Biocon Pharma Limited (76.2% of imports, $40.9M).

What is Biocon Pharma Inc's total pharmaceutical import value?

Biocon Pharma Inc's total pharmaceutical import value from India is $110.0M, based on 2,231 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Biocon Pharma Inc focus on?

Biocon Pharma Inc imports across 4 categories. The largest: Vitamins & Supplements (51.1%), Cardiovascular (41.5%), Gastrointestinal (6.9%).

Get Full Biocon Pharma Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.